Related Experiment Videos
Glicoprotein (GP) IIb/IIIa inhibitors for acute stroke treatment
Julien Bogousslavsky1, Maurizio Paciaroni, Virgilio Gallai
1Department of Neurology, CHUV, University of Lausanne, Lausanne, Switzerland.
Clinical and Experimental Hypertension (New York, N.Y. : 1993)
|November 27, 2002
Abstract:
The benefit of antiplatelet therapy remains unclear, although it does appear that aspirin monotherapy started within 48 hours of stroke onset may result in a modest clinical improvement. Glicoprotein (GP) IIb/IIIa antagonists are currently considered the most powerful specific inhibitors of platelet activation in acute thrombosis. Glicoprotein IIb/IIIa inhibitor therapy could merit a prominent role also in the initial management of patients with acute ischemic stroke. Abciximab may be promising in this setting and should be evaluated in further clinical trials.